KR101641401B1 - Ｄｏｐａ 데카르복실라제 억제제의 연속투여용 조성물 - Google Patents

Ｄｏｐａ 데카르복실라제 억제제의 연속투여용 조성물 Download PDF

Info

Publication number
KR101641401B1
KR101641401B1 KR1020117030315A KR20117030315A KR101641401B1 KR 101641401 B1 KR101641401 B1 KR 101641401B1 KR 1020117030315 A KR1020117030315 A KR 1020117030315A KR 20117030315 A KR20117030315 A KR 20117030315A KR 101641401 B1 KR101641401 B1 KR 101641401B1
Authority
KR
South Korea
Prior art keywords
carbidopa
levodopa
administration
disease
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117030315A
Other languages
English (en)
Korean (ko)
Other versions
KR20120027371A (ko
Inventor
오론 야코비-제에비
마라 네마스
Original Assignee
뉴로덤 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42320738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101641401(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 뉴로덤 엘티디 filed Critical 뉴로덤 엘티디
Publication of KR20120027371A publication Critical patent/KR20120027371A/ko
Application granted granted Critical
Publication of KR101641401B1 publication Critical patent/KR101641401B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/10—Hydrazines
    • C07C243/12—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
    • C07C243/16—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C243/18—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020117030315A 2009-05-19 2010-05-17 Ｄｏｐａ 데카르복실라제 억제제의 연속투여용 조성물 Active KR101641401B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17951109P 2009-05-19 2009-05-19
US61/179,511 2009-05-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167019114A Division KR101709904B1 (ko) 2009-05-19 2010-05-17 Dopa 데카르복실라제 억제제의 연속투여용 조성물

Publications (2)

Publication Number Publication Date
KR20120027371A KR20120027371A (ko) 2012-03-21
KR101641401B1 true KR101641401B1 (ko) 2016-07-20

Family

ID=42320738

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117030315A Active KR101641401B1 (ko) 2009-05-19 2010-05-17 Ｄｏｐａ 데카르복실라제 억제제의 연속투여용 조성물
KR1020167019114A Active KR101709904B1 (ko) 2009-05-19 2010-05-17 Dopa 데카르복실라제 억제제의 연속투여용 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167019114A Active KR101709904B1 (ko) 2009-05-19 2010-05-17 Dopa 데카르복실라제 억제제의 연속투여용 조성물

Country Status (26)

Country Link
US (9) US8193243B2 (enExample)
EP (3) EP3192500B1 (enExample)
JP (3) JP5643297B2 (enExample)
KR (2) KR101641401B1 (enExample)
CN (2) CN104546700B (enExample)
AR (3) AR078413A1 (enExample)
AU (1) AU2010250766B2 (enExample)
BR (1) BRPI1011031B8 (enExample)
CA (1) CA2761624C (enExample)
CL (1) CL2011002895A1 (enExample)
CY (1) CY1119495T1 (enExample)
DK (2) DK2432454T3 (enExample)
ES (2) ES2840748T3 (enExample)
HR (2) HRP20170805T1 (enExample)
HU (2) HUE033388T2 (enExample)
IL (1) IL216383A (enExample)
LT (1) LT2432454T (enExample)
MX (2) MX2011012315A (enExample)
NZ (1) NZ596963A (enExample)
PL (2) PL2432454T3 (enExample)
PT (2) PT3192500T (enExample)
RU (3) RU2678839C2 (enExample)
SG (3) SG10201709016RA (enExample)
SI (1) SI2432454T1 (enExample)
WO (1) WO2010134074A1 (enExample)
ZA (1) ZA201109037B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160091424A (ko) * 2009-05-19 2016-08-02 뉴로덤 엘티디 Dopa 데카르복실라제 억제제의 연속투여용 조성물

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN192600B (enExample) * 1996-10-18 2004-05-08 Hoechst Celanese Corp
PL2640358T3 (pl) 2010-11-15 2018-06-29 Neuroderm Ltd Ciągłe podawanie l-dopy, inhibitorów dopa-dekarboksylazy, inhibitorów katecholo-o-metylotransferazy i ich kompozycji
NZ703341A (en) 2012-06-05 2016-11-25 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
CN103845318A (zh) * 2012-12-07 2014-06-11 天津市汉康医药生物技术有限公司 恩他卡朋分散片
BR112015022390A8 (pt) * 2013-03-13 2019-11-26 Neuroderm Ltd uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson
KR102457026B1 (ko) * 2013-11-05 2022-10-21 신애질 코포레이션 입을 통한 연속적 약물 전달
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
CN106413754B (zh) * 2014-03-13 2019-11-29 纽罗德姆有限公司 多巴脱羧酶抑制剂组合物
WO2016036308A1 (en) 2014-09-04 2016-03-10 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof
TWI755257B (zh) 2014-10-21 2022-02-11 美商艾伯維有限公司 卡比多巴及左旋多巴之前藥及使用方法
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
KR20180004756A (ko) 2015-05-06 2018-01-12 신애질 코포레이션 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
BR112018010564A2 (pt) 2015-11-24 2018-11-21 Neuroderm Ltd. composições farmacêuticas compreendendo levodopa amida e usos das mesmas
WO2017177262A1 (en) * 2016-04-11 2017-10-19 University Of Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
US10064834B2 (en) 2016-05-09 2018-09-04 Texas Tech University System Carbidopa for the treatment of cancer
CN110753538A (zh) 2017-06-05 2020-02-04 迪兹林制药公司 左旋多巴输注溶液
US20230123806A1 (en) * 2017-07-07 2023-04-20 Neuroderm, Ltd. Device for subcutaneous delivery of fluid medicament
CN111954523A (zh) * 2018-03-29 2020-11-17 艾维制药有限责任公司 左旋多巴分次剂量组合物及用途
EP3880210A1 (en) 2018-11-15 2021-09-22 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
WO2020252257A1 (en) * 2019-06-12 2020-12-17 President And Fellows Of Harvard College Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
JP2023538859A (ja) * 2020-08-31 2023-09-12 パーデュー、ファーマ、リミテッド、パートナーシップ レボドパ送達のための組成物及び方法
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
CA3196650A1 (en) * 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen
WO2023126945A1 (en) * 2022-01-03 2023-07-06 Neuroderm, Ltd. Methods and compositions for treating parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006006929A1 (en) * 2004-07-12 2006-01-19 Dizlin Medical Design Ab Infusion and injection solution of levodopa
US20080051459A1 (en) * 2006-05-31 2008-02-28 Solvay Pharmaceuticals Gmbh Long term 24-hour intestinal administration of levodopa/carbidopa

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
AU6889274A (en) * 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
US3936495A (en) * 1973-11-27 1976-02-03 Merck & Co., Inc. Purification process
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4241082A (en) 1977-09-02 1980-12-23 Sankyo Company Limited Agents for promoting reproductive ability of domestic animals
JPS5450700A (en) 1977-09-28 1979-04-20 Sankyo Co Glazing agent of animal leather
JPS6021570B2 (ja) * 1978-07-04 1985-05-28 三共株式会社 ド−パ類の高濃度製剤の製法
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4642316A (en) * 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
DE252290T1 (de) * 1986-06-10 1988-06-09 Chiesi Farmaceutici S.P.A., Parma Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4684666A (en) * 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5350769A (en) * 1990-10-30 1994-09-27 Ss Pharmaceutical Co., Ltd. Antiinflammatory gel preparation
US5877176A (en) * 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
GB9523833D0 (en) 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US5861423A (en) * 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
WO1999048876A1 (en) * 1998-03-20 1999-09-30 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US7201923B1 (en) * 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
EP1077692B1 (en) * 1998-05-15 2004-07-28 Warner-Lambert Company LLC Amino acid stabilized gabapentin and pregabalin preparations and process for preparing the same
US6274168B1 (en) * 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2000054773A1 (en) 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US7479498B2 (en) * 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
US6348965B1 (en) * 1999-09-24 2002-02-19 Henry Palladino Solid state fluorescence and absorption spectroscopy
SE0001151D0 (sv) 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
US20020028799A1 (en) 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction
GB0017387D0 (en) * 2000-07-14 2000-08-30 Pfizer Ltd Novel enzyme
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US20030119714A1 (en) 2000-12-15 2003-06-26 Naylor Alasdair Mark Treatment of male sexual dysfunction
WO2003050261A2 (en) 2001-12-10 2003-06-19 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
EA200401334A1 (ru) * 2002-04-11 2005-04-28 Ранбакси Лабораторис Лимитед Фармацевтические композиции карбидопы и леводопы с контролируемым высвобождением
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
ATE463494T1 (de) 2002-10-10 2010-04-15 Morphochem Ag Komb Chemie Neue verbindungen mit antibakterieller aktivität
US20050147687A1 (en) * 2003-07-18 2005-07-07 Julia Rashba-Step Methods for fabrication, uses and compositions of small spherical particles of AAT prepared by controlled phase separation
US7589233B2 (en) * 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
ATE495739T1 (de) * 2003-08-29 2011-02-15 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
US20050053669A1 (en) 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
KR20060108692A (ko) * 2003-10-31 2006-10-18 알자 코포레이션 메트포르민의 개선된 흡수를 위한 조성물 및 제형
CN1901881A (zh) * 2003-10-31 2007-01-24 阿尔扎公司 用于增强的吸收的组合物和剂型
WO2005099678A1 (en) 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
DK1797109T3 (en) * 2004-09-09 2016-04-11 Yeda Res & Dev MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
WO2006037061A2 (en) * 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
WO2006043532A1 (ja) * 2004-10-19 2006-04-27 Ono Pharmaceutical Co., Ltd. パーキンソン病治療剤
DE102006021872B4 (de) 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8058243B2 (en) 2006-10-13 2011-11-15 Hsc Research And Development Limited Partnership Method for treating a brain cancer with ifenprodil
US8563013B2 (en) * 2007-04-06 2013-10-22 Janssen Biotech, Inc. Systems and methods for delivering a fluid drug
CN101669925B (zh) 2008-09-10 2011-08-10 天津药物研究院 干粉吸入剂、其制备方法和用途
RU2678839C2 (ru) 2009-05-19 2019-02-04 Неуродерм Лтд Композиции для непрерывного введения ингибиторов допа-декарбоксилазы
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
CN101987081B (zh) 2010-07-16 2012-08-08 钟术光 一种控释制剂
KR101187064B1 (ko) 2010-07-18 2012-09-28 주식회사 바이오폴리메드 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
RS57334B1 (sr) 2010-11-15 2018-08-31 Neuroderm Ltd Kompozicije za transdermalno davanje aktivnih sredstava
PL2640358T3 (pl) 2010-11-15 2018-06-29 Neuroderm Ltd Ciągłe podawanie l-dopy, inhibitorów dopa-dekarboksylazy, inhibitorów katecholo-o-metylotransferazy i ich kompozycji
SG191090A1 (en) 2010-12-10 2013-07-31 Synagile Corp Subcutaneously infusible levodopa prodrug compositions and methods of infusion
WO2013061161A2 (en) 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
BR112015022390A8 (pt) 2013-03-13 2019-11-26 Neuroderm Ltd uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson
CN106413754B (zh) 2014-03-13 2019-11-29 纽罗德姆有限公司 多巴脱羧酶抑制剂组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006006929A1 (en) * 2004-07-12 2006-01-19 Dizlin Medical Design Ab Infusion and injection solution of levodopa
US20080051459A1 (en) * 2006-05-31 2008-02-28 Solvay Pharmaceuticals Gmbh Long term 24-hour intestinal administration of levodopa/carbidopa

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160091424A (ko) * 2009-05-19 2016-08-02 뉴로덤 엘티디 Dopa 데카르복실라제 억제제의 연속투여용 조성물
KR101709904B1 (ko) 2009-05-19 2017-02-23 뉴로덤 엘티디 Dopa 데카르복실라제 억제제의 연속투여용 조성물

Also Published As

Publication number Publication date
CA2761624C (en) 2016-10-18
HUE033388T2 (en) 2017-12-28
CA2761624A1 (en) 2010-11-25
CN102438587A (zh) 2012-05-02
CN102438587B (zh) 2015-08-19
WO2010134074A1 (en) 2010-11-25
US7863336B2 (en) 2011-01-04
HUE052685T2 (hu) 2021-05-28
US20140249230A1 (en) 2014-09-04
CN104546700A (zh) 2015-04-29
US9993451B2 (en) 2018-06-12
US20140249231A1 (en) 2014-09-04
KR20160091424A (ko) 2016-08-02
SG10201505101VA (en) 2015-07-30
AU2010250766B2 (en) 2015-04-09
US20100298428A1 (en) 2010-11-25
DK2432454T3 (en) 2017-06-19
DK3192500T3 (da) 2020-12-21
US20100298429A1 (en) 2010-11-25
AU2010250766A1 (en) 2012-01-12
US9040590B2 (en) 2015-05-26
ZA201109037B (en) 2013-02-27
SG10201709016RA (en) 2017-11-29
JP2016121199A (ja) 2016-07-07
PT2432454T (pt) 2017-06-12
HRP20170805T1 (hr) 2017-08-25
US20190125708A1 (en) 2019-05-02
JP2015017144A (ja) 2015-01-29
CY1119495T1 (el) 2018-03-07
RU2015115064A (ru) 2015-11-20
SG176159A1 (en) 2011-12-29
AR117412A2 (es) 2021-08-04
JP6157678B2 (ja) 2017-07-05
RU2011149976A (ru) 2013-06-27
HRP20202038T1 (hr) 2021-03-05
JP5921002B2 (ja) 2016-05-24
US9101663B2 (en) 2015-08-11
IL216383A (en) 2016-02-29
PL3192500T3 (pl) 2021-04-06
PL2432454T3 (pl) 2017-10-31
IL216383A0 (en) 2012-01-31
CL2011002895A1 (es) 2012-10-12
LT2432454T (lt) 2017-07-10
BRPI1011031B8 (pt) 2021-05-25
BRPI1011031A2 (pt) 2016-08-16
AR078413A1 (es) 2011-11-09
NZ596963A (en) 2014-01-31
RU2559083C2 (ru) 2015-08-10
US20210077442A1 (en) 2021-03-18
KR20120027371A (ko) 2012-03-21
EP3192500A1 (en) 2017-07-19
PT3192500T (pt) 2021-01-05
KR101709904B1 (ko) 2017-02-23
ES2627655T3 (es) 2017-07-31
EP2432454B1 (en) 2017-03-01
AR117502A2 (es) 2021-08-11
US20110269833A1 (en) 2011-11-03
SI2432454T1 (sl) 2017-09-29
EP2432454A1 (en) 2012-03-28
CN104546700B (zh) 2017-06-06
ES2840748T3 (es) 2021-07-07
US8193243B2 (en) 2012-06-05
JP2012527447A (ja) 2012-11-08
RU2678839C2 (ru) 2019-02-04
EP3777839A1 (en) 2021-02-17
MX364974B (es) 2019-05-16
US9040589B2 (en) 2015-05-26
RU2019101159A (ru) 2020-07-16
EP3192500B1 (en) 2020-12-02
US20160151317A1 (en) 2016-06-02
BRPI1011031B1 (pt) 2020-06-23
MX2011012315A (es) 2011-12-16
RU2559083C9 (ru) 2016-01-20
US20230321019A1 (en) 2023-10-12
JP5643297B2 (ja) 2014-12-17

Similar Documents

Publication Publication Date Title
KR101641401B1 (ko) Ｄｏｐａ 데카르복실라제 억제제의 연속투여용 조성물
US20170157077A1 (en) Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
HK40046868A (en) Compositions for continuous administration of dopa decarboxylase inhibitors
HK1168557B (en) Compositions for continuous administration of dopa decarboxylase inhibitors
HK1168557A (en) Compositions for continuous administration of dopa decarboxylase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20111219

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150324

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20150324

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150609

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20151007

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150609

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20151007

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20150804

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150324

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151211

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20160426

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20160202

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20151104

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20151007

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20150804

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20150324

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160714

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20160714

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20160714

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20190703

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20190703

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20200626

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20210630

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20220630

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20230629

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20240625

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20250625

Start annual number: 10

End annual number: 10